Indantadol (hydrochloride)

Indantadol hydrochloride (CHF-3381) is an orally active, non-selective NMDA antagonist and MAO inhibitor. Indantadol hydrochloride blocks the binding of [³H]-MK-801 to NMDA receptors in a non-competitive manner, with an IC50 of 8.1 μM. Indantadol hydrochloride completely inhibits dopamine release caused by NMDA. Indantadol hydrochloride protects neurons, with an ED₅₀ of 35 μM. Indantadol hydrochloride has anticonvulsant and anti-high pain hypersensitivity activities[1][2][3].

Product Specifications

CAS Number

[202914-18-9]

Product Name Alternative

CHF-3381

UNSPSC

12352005

Target

IGluR; Monoamine Oxidase

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/indantadol-hydrochloride.html

Smiles

O=C(CNC1CC2=C(C1)C=CC=C2)N.Cl

Molecular Formula

C11H15ClN2O

Molecular Weight

226.70

References & Citations

[1]Silvia Zucchini, et al. Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist. Neuroreport. 2022, 13, 6.|[2]Gandolfi O, et al. Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms. Pharmacol Biochem Behav. 2001 Sep;70 (1) :157-66. |[3]Mattia C, Coluzzi F. Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs. 2007 Sep;10 (9) :636-44.